Featured Research

from universities, journals, and other organizations

Early Breast Cancer: LHRH Agonists Show Considerable Promise

Date:
October 10, 2008
Source:
Wiley-Blackwell
Summary:
Women who have had early stage breast cancer surgically removed, and whose tumor cells are stimulated by the hormone estrogen, can benefit from taking luteinizing hormone releasing hormone antagonists, a Cochrane systematic review has concluded. This medication may be taken alone or alongside the use of tamoxifen.

Women who have had early stage breast cancer surgically removed, and whose tumour cells are stimulated by the hormone oestrogen, can benefit from taking Luteinizing hormone releasing hormone (LHRH) antagonists, a Cochrane Systematic Review has concluded. This medication may be taken alone or alongside the use of tamoxifen.

Developing effective treatment regimes is important because approximately 30% of women diagnosed with early stage breast cancer eventually die of the disease.

In over half of the premenopausal women who develop breast cancer, the cells in the tumours grow faster in the presence of oestrogen. Their tumours are said to be ER+. Treatment often starts with the surgical removal of the tumour, but some cancer cells may be left behind. The challenge then is to slow down their rate of growth.

A well recognised chain of events leads to oestrogen-stimulated tumour cell growth. First LHRH causes the pituitary gland to release luteinizing hormone (LH). This LH travels to the ovaries and triggers the release of oestrogen. The oestrogen moves to the region of the tumour where it locks on to receptors on the cells and stimulates tumour growth.

There are two possible ways of preventing oestrogen from stimulating growth. One is to block the oestrogen receptors that are present on the cells so that they can't respond to the hormone. Tamoxifen works this way. The second is to reduce the amount of oestrogen that is present in the bloodstream. This can be done by blocking LHRH's ability to cause a release of LH.

A team of Cochrane Researchers searched for evidence on the value of using LHRH antagonists. They identified 14 randomised trials that involved nearly 12,000 premenopausal women with operable breast cancer, most of whom were ER+. The LHRH agonist in most trials was goserelin.

"While we cannot yet recommend using ovarian suppression as the standard therapy for these women, it is possible that LHRH antagonists may reduce the risk of cancer reoccurring and extend survival times in premenopausal women who have early breast cancer that is not known to be ER negative. Given this potential, we eagerly await the results of current clinical trials that could answer this important issue," says lead researcher Rohini Sharma, who works in the Department of Medical Oncology, Hammersmith Hospital, London, UK.

The researchers point out that they were able to determine whether tamoxifen or the LHRH antagonist was better if used alone. They did find that women who used LHRH alone had fewer, or less severe, adverse effects than those on tamoxifen.

The researchers also stress the need for studies that investigate long term effects on women given the various different treatment regimes, and the need to wait for the mature results of studies in order to fully answer this important question.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Cite This Page:

Wiley-Blackwell. "Early Breast Cancer: LHRH Agonists Show Considerable Promise." ScienceDaily. ScienceDaily, 10 October 2008. <www.sciencedaily.com/releases/2008/10/081007192441.htm>.
Wiley-Blackwell. (2008, October 10). Early Breast Cancer: LHRH Agonists Show Considerable Promise. ScienceDaily. Retrieved April 18, 2014 from www.sciencedaily.com/releases/2008/10/081007192441.htm
Wiley-Blackwell. "Early Breast Cancer: LHRH Agonists Show Considerable Promise." ScienceDaily. www.sciencedaily.com/releases/2008/10/081007192441.htm (accessed April 18, 2014).

Share This



More Health & Medicine News

Friday, April 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

'Holy Grail' Of Weight Loss? New Find Could Be It

'Holy Grail' Of Weight Loss? New Find Could Be It

Newsy (Apr. 18, 2014) In a potential breakthrough for future obesity treatments, scientists have used MRI scans to pinpoint brown fat in a living adult for the first time. Video provided by Newsy
Powered by NewsLook.com
Little Progress Made In Fighting Food Poisoning, CDC Says

Little Progress Made In Fighting Food Poisoning, CDC Says

Newsy (Apr. 18, 2014) A new report shows rates of two foodborne infections increased in the U.S. in recent years, while salmonella actually dropped 9 percent. Video provided by Newsy
Powered by NewsLook.com
Scientists Create Stem Cells From Adult Skin Cells

Scientists Create Stem Cells From Adult Skin Cells

Newsy (Apr. 17, 2014) The breakthrough could mean a cure for some serious diseases and even the possibility of human cloning, but it's all still a way off. Video provided by Newsy
Powered by NewsLook.com
Obama: 8 Million Healthcare Signups

Obama: 8 Million Healthcare Signups

AP (Apr. 17, 2014) President Barack Obama gave a briefing Thursday announcing 8 million people have signed up under the Affordable Care Act. He blasted continued Republican efforts to repeal the law. (April 17) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins